Teva Pharmaceutical Industries Ltd.
Open
SectorHealthcare
39.54 -1.3
Overview
Share price change
24h
Min
39.11
Max
40.77
Income | -944M -575M |
|---|---|
Sales | 161M 4.1B |
P/E Sector Avg | 64.533 56.432 |
EPS | 0.64 |
Profit margin | -13.882 |
Employees | 31,173 |
EBITDA | -896M -19M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +18.63% upside |
Next Earnings | 4 Nov 2026 |
|---|
Market Cap | 8.9B 45B |
|---|---|
Previous open | 40.84 |
Previous close | 39.54 |
News Sentiment
By Acuity
40%
60%
84 / 339 Healthcare
Teva Pharmaceutical Industries Ltd. Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Teva Pharmaceutical Industries Ltd. Forecast
Price Target
By TipRanks
18.63% upside
12 Months Forecast
Average 44 USD 18.63%
High 50 USD
Low 40 USD
Based on 9 Wall Street analysts offering 12 month price targets forTeva Pharmaceutical Industries Ltd. - Dist in the last 3 months.
Sentiment
By Acuity
84 / 339 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
$
About Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
